AU2013311626A1 - Methods for identifying HIV neutralizing antibodies - Google Patents

Methods for identifying HIV neutralizing antibodies Download PDF

Info

Publication number
AU2013311626A1
AU2013311626A1 AU2013311626A AU2013311626A AU2013311626A1 AU 2013311626 A1 AU2013311626 A1 AU 2013311626A1 AU 2013311626 A AU2013311626 A AU 2013311626A AU 2013311626 A AU2013311626 A AU 2013311626A AU 2013311626 A1 AU2013311626 A1 AU 2013311626A1
Authority
AU
Australia
Prior art keywords
binding
cell
hiv
fusion protein
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013311626A
Other languages
English (en)
Inventor
Julian Miguel Blanco Arbues
Jorge Carrillo Molina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IrsiCaixa Institut de Recerca de la Sida
Esteve Pharmaceuticals SA
Original Assignee
IrsiCaixa Institut de Recerca de la Sida
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IrsiCaixa Institut de Recerca de la Sida, Laboratorios del Dr Esteve SA filed Critical IrsiCaixa Institut de Recerca de la Sida
Publication of AU2013311626A1 publication Critical patent/AU2013311626A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
AU2013311626A 2012-09-06 2013-09-06 Methods for identifying HIV neutralizing antibodies Abandoned AU2013311626A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12382342.9 2012-09-06
EP12382342.9A EP2706356A1 (en) 2012-09-06 2012-09-06 Methods for identifying HIV neutralizing antibodies
PCT/EP2013/068446 WO2014037490A1 (en) 2012-09-06 2013-09-06 Methods for identifying hiv neutralizing antibodies

Publications (1)

Publication Number Publication Date
AU2013311626A1 true AU2013311626A1 (en) 2015-04-30

Family

ID=46829683

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013311626A Abandoned AU2013311626A1 (en) 2012-09-06 2013-09-06 Methods for identifying HIV neutralizing antibodies

Country Status (16)

Country Link
US (1) US9952218B2 (https=)
EP (2) EP2706356A1 (https=)
JP (1) JP6282655B2 (https=)
KR (1) KR20150081255A (https=)
CN (1) CN104755933B (https=)
AU (1) AU2013311626A1 (https=)
BR (1) BR112015004970A2 (https=)
CA (1) CA2884165A1 (https=)
ES (1) ES2643268T3 (https=)
IL (1) IL237613A0 (https=)
IN (1) IN2015DN02730A (https=)
MX (1) MX2015003047A (https=)
PT (1) PT2893349T (https=)
RU (1) RU2015112297A (https=)
WO (1) WO2014037490A1 (https=)
ZA (1) ZA201502210B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106166313B (zh) * 2016-07-01 2018-09-07 浙江大学 一种艾滋病孕妇血液净化器
CN106075626B (zh) * 2016-07-01 2018-06-26 浙江大学 一种艾滋病血液净化治疗仪

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US7115262B1 (en) * 1999-03-16 2006-10-03 The United States Of America As Represented By The Department Of Health And Human Services Chimeric protein for prevention and treatment of HIV infection
WO2003040311A2 (en) * 2001-10-25 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
EP1523492A4 (en) * 2002-07-23 2006-05-10 Univ Duke IGG FC / HIV GP120 / C3D FUSION PROTEIN
US8197819B2 (en) * 2004-06-08 2012-06-12 Novartis Vaccines And Diagnostics, Inc. Env polypeptide complexes and methods of use
ATE471947T1 (de) * 2005-02-03 2010-07-15 Novartis Vaccines & Diagnostic Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür
CN101551392A (zh) * 2008-01-22 2009-10-07 厦门大学 一种检测人乳头瘤病毒中和抗体的方法
CN101846679A (zh) * 2009-03-25 2010-09-29 邢安辉 筛选含有外源融合基因HIV/env/IFNα-2b的重组痘苗病毒的方法
EP3957651A1 (en) * 2010-05-21 2022-02-23 The United States of America, as Represented By the Secretary, Department of Health and Human Services High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins

Also Published As

Publication number Publication date
PT2893349T (pt) 2018-04-12
WO2014037490A1 (en) 2014-03-13
IN2015DN02730A (https=) 2015-09-04
MX2015003047A (es) 2015-07-14
KR20150081255A (ko) 2015-07-13
CN104755933B (zh) 2017-06-09
CA2884165A1 (en) 2014-03-13
EP2706356A1 (en) 2014-03-12
EP2893349B1 (en) 2017-08-16
CN104755933A (zh) 2015-07-01
EP2893349A1 (en) 2015-07-15
JP6282655B2 (ja) 2018-02-21
ZA201502210B (en) 2016-11-30
JP2015530575A (ja) 2015-10-15
US9952218B2 (en) 2018-04-24
RU2015112297A (ru) 2016-10-27
ES2643268T3 (es) 2017-11-21
US20150233924A1 (en) 2015-08-20
IL237613A0 (en) 2015-04-30
HK1211694A1 (en) 2016-05-27
BR112015004970A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
US20250129171A1 (en) Car t-cell therapy directed to lhr for the treatment of solid tumors
Ou et al. Role of protein disulfide isomerase and other thiol-reactive proteins in HIV-1 envelope protein-mediated fusion
Groom et al. Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome
US10711064B2 (en) Lym-1 and Lym-2 targeted CAR cell immunotherapy
AU723158B2 (en) Fluorescence resonance energy transfer screening assay for the identification of HIV-1 envelope glycoprotein-medicated cell
Bego et al. Vpu exploits the cross-talk between BST2 and the ILT7 receptor to suppress anti-HIV-1 responses by plasmacytoid dendritic cells
Wang et al. Enhanced SARS-CoV-2 neutralization by secretory IgA in vitro
US10722571B2 (en) Rabies virus G protein epitope, and rabies virus neutralising binding molecule that binds specifically thereto
US20250296985A1 (en) Potently neutralizing novel human monoclonal antibodies against sars-cov-2 (covid-19)
Armani-Tourret et al. Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesis
Toyoda et al. Impaired ability of Nef to counteract SERINC5 is associated with reduced plasma viremia in HIV-infected individuals
US9952218B2 (en) Methods for identifying HIV neutralizing antibodies
US8637234B2 (en) Molecular scaffolds for HIV-1 epitopes
Lopalco et al. Anti-CD4 antibodies in exposed seronegative adults and in newborns of HIV type 1-seropositive mothers: a follow-up study
Thordsen et al. Infection of cells expressing CXCR4 mutants lacking N-glycosylation at the N-terminal extracellular domain is enhanced for R5X4-dualtropic human immunodeficiency virus type-1
CN114316062B (zh) 靶向HIV gp120蛋白和人CD3分子的多特异性抗体及其应用
HK1211694B (en) Methods for identifying hiv neutralizing antibodies
Carrillo et al. Gp120/CD4 blocking antibodies are frequently elicited in ART-naive chronically HIV-1 infected individuals
Eslahpazir et al. Infection of macrophages and dendritic cells with primary R5-tropic human immunodeficiency virus type 1 inhibited by natural polyreactive anti-CCR5 antibodies purified from cervicovaginal secretions
Ferraz et al. High-throughput, functional screening of the anti-HIV-1 humoral response by an enzymatic nanosensor
Nora et al. Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma viruses
Gapp Mechanistic insight into the CD32-driven enhancement of HIV-1 susceptibility of resting CD4 T cells
US20070092939A1 (en) Human immunodeficiency virus entry inhibitor assay
MX2008012721A (es) Composiciones y metodos para el analisis y tratamiento de sindrome de consuncion por sida y disfuncion de celulas inmunes.
畑山靖佳 et al. Development of a Monoclonal Antibody Targeting HTLV-1 Envelope gp46 Glycoprotein and Its Application to Near-Infrared Photoimmuno-Antimicrobial Strategy

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period